Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 6/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1728733 | 0.80 | CA1 (0.47) | MAPTGAAALDH1A1MEN1KMT2A | |
| SCHEMBL931749 | 0.79 | MAPT (0.56) | MAPTGAAALDH1A1MEN1KMT2A | |
| SCHEMBL1565673 | 0.77 | ALDH1A1 (0.42) | MAPTGAAALDH1A1MEN1KMT2A | |
| SCHEMBL1259735 | 0.77 | POLB (0.49) | MAPTGAAALDH1A1MEN1KMT2A | |
| SCHEMBL4147798 | 0.76 | MAPT (0.37) | MAPTGAAALDH1A1MEN1KMT2A | |
| SCHEMBL8575116 | 0.76 | LOXL2 (0.40) | MAPTGAAALDH1A1MEN1KMT2A | |
| SCHEMBL6216871 | 0.75 | MAPT (0.41) | MAPTGAAALDH1A1MEN1KMT2A | |
| SCHEMBL7005993 | 0.75 | ADRB3 (0.43) | MAPTMEN1KMT2AKDM4ERET | |
| Ammonia Solution, Strong SCHEMBL6701042 | 0.75 | ALDH1A1 (0.44) | MAPTGAAALDH1A1MEN1KMT2A | |
| SCHEMBL1728835 | 0.74 | HPGD (0.47) | MAPTALDH1A1MEN1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293768-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-20120004164-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2012-01-05 | — | — | US | disclosed |
| US-8063084-B2 | Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid levels | NOVARTIS AG (CH) | 2011-11-22 | — | — | US | disclosed |
| US-20100233116-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2010-09-16 | — | — | US | disclosed |
| EP-2054408-A2 | HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DISEASES RELATED TO ELEVATED LIPID LEVEL | Novartis Ag (CH) | 2009-05-06 | — | — | EP | disclosed |
| WO-2008127349-A2 | HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DISEASES RELATED TO ELEVATED LIPID LEVEL | NOVARTIS AG (CH) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100233116-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | MAPT 3107/4885GAA 610/4885ALDH1A1 433/4885 |
| US-20120004164-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | MAPT 2947/4885GAA 556/4885ALDH1A1 451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.